GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunityBio Inc (NAS:IBRX) » Definitions » Net Change in Cash

IBRX (ImmunityBio) Net Change in Cash : $-121.88 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is ImmunityBio Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

ImmunityBio's Net Change in Cash for the three months ended in Dec. 2024 was $31.61 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 was $-121.88 Mil.

ImmunityBio Net Change in Cash Historical Data

The historical data trend for ImmunityBio's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunityBio Net Change in Cash Chart

ImmunityBio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Change in Cash
Get a 7-Day Free Trial -40.89 146.19 -76.32 160.82 -121.88

ImmunityBio Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 87.49 -132.42 -2.93 -18.14 31.61

ImmunityBio Net Change in Cash Calculation

ImmunityBio's Net Change in Cash for the fiscal year that ended in Dec. 2024 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-391.236+-12.246+281.63+-0.023
=-121.88

ImmunityBio's Net Change in Cash for the quarter that ended in Dec. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-85.144+9.834+106.929+-0.007
=31.61

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-121.88 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmunityBio Net Change in Cash Related Terms

Thank you for viewing the detailed overview of ImmunityBio's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmunityBio Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunityBio Inc (NAS:IBRX) » Definitions » Net Change in Cash
Comparable Companies
XENE FOLD BHVN MLTX ACAD VKTX MTSR NAMS CPRX PTGX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
26CA:Germany
Address
3530 John Hopkins Court, San Diego, CA, USA, 92121
Website
https://www.immunitybio.com
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
Executives
Patrick Soon-shiong director, 10 percent owner, officer: See remarks 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
California Capital Equity, Llc 10 percent owner 10182 CULVER BOULEVARD, CULVER CITY CA 90232
Nant Capital, Llc 10 percent owner 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Cambridge Equities, Lp 10 percent owner 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Mp 13 Ventures, Llc 10 percent owner 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Michael D Blaszyk director C/O NANTKWEST, INC., 2533 SOUTH COAST HIGHWAY 101, SUITE 210, CARDIFF-BY-THE-SEA CA 92007
John Owen Brennan director C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Wesley Clark director C/O ARGYLE SECURITY ACQUISITION CORP., 200 CONCORD PLAZA, SUITE 700, SAN ANTONIO TX 78216
Regan J Lauer officer: Chief Accounting Officer 4250 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA 92037
Richard Adcock officer: Chief Executive Officer C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Cheryl Cohen director C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Linda Maxwell director 1040 SPRING STREET, SILVER SPRING NC 27709
Christobel Selecky director C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
David C. Sachs officer: Chief Financial Officer C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Frederick W Driscoll director